Five things for pharma marketers to know: Friday, May 27, 2016

1. Johnson & Johnson's brand score has dropped since a jury decision in early 2016 found that the drugmaker's use of talc in its baby powder products caused ovarian cancer. The brand score, tracked by YouGov BrandIndex Buzz, fell from 18.1 in February to 5.4 in May. (Ad Age)

2. Military researchers said a patient in the U.S. had been infected with bacteria resistant to an antibiotic that is considered the last resort against superbugs. (We reported earlier this week that drugmakers like Allergan have renewed their interest in developing treatments for patients with carbapenem-resistant bacteria, called CRE.) (NYT)

3. Valeant reportedly rejected an acquisition proposal from Takeda Pharmaceutical and private-equity firm TPG. The proposal occurred before Valeant's new CEO, Joseph Papa, took over the drugmaker. (WSJ)

4. The FDA approved the first buprenorphine implant, Probuphine, for opioid addiction. Titan Pharmaceuticals, which developed the treatment, said it plans to begin sales this summer at a price lower than other long-acting medications on the market. (Forbes)

5. IMS Health acquired Privacy Analytics, which developed technology to anonymize private healthcare data. IMS Health a few weeks ago announced a merger with Quintiles Transnational in an all-stock deal worth about $8.75 billion.